References
- D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43:368–382
- Finazzi G, Barbui T. The treatment of polycythemia vera: an update in the JAK2 era. Intern Emerg Med. 2007;2:13–18
- Beall CM, Cavalleri GL, Deng L, et al. Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders. PNAS. 2010;107:11459–11464
- Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30:621--631
- Rennke HG, Klein PS. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis. 1989;13:443--456
- Kosch M, August C, Hausberg M, et al. Focal sclerosis with tip lesions secondary to polycythemia vera. Nephrol Dial Transplant. 2000;15(10):1710–1711
- Mary FM. Idiopathic erythrocytosis: a disappearing entity. Hematology. 2009;1:629–635
- Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116(16):3039–3048
- Moore LG. Human genetic adaptation to high altitude. High Alt Med Biol. 2001;2(2):257–279
- Martha W, Ayalew T. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010;91:174–179
- Sukru U, Gulsum O, Mehmet S, et al. Absence of hypoalbuminemia despite nephrotic proteinuria in focal segmental glomerulosclerosis secondary to polycythemia vera. Intern Med. 2010;49:2477–2480
- Claire H. Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. Hematology. 2010;1:129–134